Exact Mass: 598.3438

Avermectin A1a aglycone

C35H50O8 (598.3506)

LysoPI(18:1(9Z)/0:0)

C27H51O12P (598.3118)

LysoPI(18:1(9Z)/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(18:1(9Z)/0:0), in particular, consists of one chain of oleic acid at the C-1 position.

H-Phe-D-met-arg-phe-NH2

C29H42N8O4S (598.305)

PI(18:1(9Z)/0:0)

C27H51O12P (598.3118)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C31H51O9P (598.3271)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0)

C31H51O9P (598.3271)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C31H51O9P (598.3271)

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0)

C31H51O9P (598.3271)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C31H51O9P (598.3271)

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0)

C31H51O9P (598.3271)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Cussoracoside F

C31H50O11 (598.3353)

12-O-Methylvolkensin

C34H46O9 (598.3142)

Cyl-2

C32H46N4O7 (598.3366)

Bacobitacin B

C34H46O9 (598.3142)

Gambogin

C38H46O6 (598.3294)

L006181

C30H42N6O7 (598.3115)

FA-70D

C30H42N6O7 (598.3115)

Cinnafragrin D

C34H46O9 (598.3142)

Sarcohydroquinone sulfate A

C36H54O5S (598.3692)

Salannol 3-acetate

C34H46O9 (598.3142)

Phosphatidylinositol lyso 18:1

C27H51O12P (598.3118)

6alpha-Acetoxyhavanensin acetate

C34H46O9 (598.3142)

16-Oxo-21-episerratriol triacetate

C36H54O7 (598.3869)

3-(Hydrogen suberoyl)-Cinobufagin

C34H46O9 (598.3142)

Picrasinoside D

C30H46O12 (598.2989)

6beta,7beta-diacetoxy-8,13-epoxy-labd-14-en-11-one-1alpha-O-beta-glucopyranoside|forskoditerpenoside D

C30H46O12 (598.2989)

Wikstrotoxin A

C35H50O8 (598.3506)

C34H46O9

C34H46O9 (598.3142)

LL-F28249gamma|nemadectin B|S541 Factor A

C35H50O8 (598.3506)

salannol-3-acetate

C34H46O9 (598.3142)

Di-Ac-Flavidulol C

C38H46O6 (598.3294)

(6S,13S)-cleroda-3,14-diene-6,13-diol 13-O-beta-L-fucopyranosyl-(1-2)-alpha-L-rhamnopyranoside

C32H54O10 (598.3717)

Mugil visceroactive peptide-1|SGPAGVLamide

C26H46N8O8 (598.3438)

C32H54O10

C32H54O10 (598.3717)

linckoside J

C32H54O10 (598.3717)

adociasulfate 11

C36H54O5S (598.3692)

(24S)-3beta-hydroxy-24,25-oxiirane-16,23-dione-9,10-seco-9,19-cyclolanost-1(10),7(8),9(11)-trien 3-O-beta-D-xylopyranoside|isocimipodocarpaside

C35H50O8 (598.3506)

rehmaglutosides F

C30H46O12 (598.2989)

munronoid N

C34H46O9 (598.3142)

(6S,13S)-13-O-beta-L-fucopyranosyl-6-O-alpha-L-rhamnopyranosylcleroda-3,14-diene-6,13-diol

C32H54O10 (598.3717)

Antibiotic S541D

C35H50O8 (598.3506)

3-O-beta-D-xylopyranosylholosta-7,9(11),22E,24-tetraene-3beta,17alpha-diol|nobiliside A

C35H50O8 (598.3506)

tedanolide C

C31H50O11 (598.3353)

Antibiotic S451B

C35H50O8 (598.3506)

C31H50O11

C31H50O11 (598.3353)

S541 Factor C

C35H50O8 (598.3506)

24,25-epoxy-1,7-diacetoxy-1alpha,7alpha-dihydroxy-14,18-cycloapotirucalla-20(22)-en-3,4:20,23-diolide|simaroubin C

C34H46O9 (598.3142)

VM-44864

C35H50O8 (598.3506)

Di-Ac-Serratamolide

C30H50N2O10 (598.3465)

kurilensoside G

C32H54O10 (598.3717)

24,25-epoxy-1,7-diacetoxy-1alpha,7alpha-dihydroxyapotirucalla-14,20(22)-dien-3,4:20,23-diolide|simaroubin D

C34H46O9 (598.3142)

3-O-[beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside]-5alpha,14alpha-androst-8-ene

C31H50O11 (598.3353)

embelinol

C36H54O7 (598.3869)

1beta,8beta-diacetoxy-9beta-cinnamoyloxy-2beta-hexanoyloxy-beta-dihydroagarofuran

C34H46O9 (598.3142)

Ala Pro Arg Lys Lys

C26H50N10O6 (598.3915)

12b-O-[deca-2E,4Z-dienoyl]-13a-(2-methylbutyl)-4b-phorbol

C35H50O8 (598.3506)

12b-O-[deca-2Z,4E-dienoyl]-13a-isobutyl-5-ene-7-oxo-4b-phorbol

C34H46O9 (598.3142)

His Met Arg Arg

C23H42N12O5S (598.3122)

His Arg Met Arg

C23H42N12O5S (598.3122)

His Arg Arg Met

C23H42N12O5S (598.3122)

His Arg Thr Trp

C27H38N10O6 (598.2976)

His Arg Trp Thr

C27H38N10O6 (598.2976)

His Thr Arg Trp

C27H38N10O6 (598.2976)

His Thr Trp Arg

C27H38N10O6 (598.2976)

His Trp Arg Thr

C27H38N10O6 (598.2976)

His Trp Thr Arg

C27H38N10O6 (598.2976)

Met His Arg Arg

C23H42N12O5S (598.3122)

Met Arg His Arg

C23H42N12O5S (598.3122)

Met Arg Arg His

C23H42N12O5S (598.3122)

Arg His Met Arg

C23H42N12O5S (598.3122)

Arg His Arg Met

C23H42N12O5S (598.3122)

Arg His Thr Trp

C27H38N10O6 (598.2976)

Arg His Trp Thr

C27H38N10O6 (598.2976)

Arg Met His Arg

C23H42N12O5S (598.3122)

Arg Met Arg His

C23H42N12O5S (598.3122)

Arg Arg His Met

C23H42N12O5S (598.3122)

Arg Arg Met His

C23H42N12O5S (598.3122)

Arg Thr His Trp

C27H38N10O6 (598.2976)

Arg Thr Trp His

C27H38N10O6 (598.2976)

Arg Trp His Thr

C27H38N10O6 (598.2976)

Arg Trp Thr His

C27H38N10O6 (598.2976)

Thr His Arg Trp

C27H38N10O6 (598.2976)

Thr His Trp Arg

C27H38N10O6 (598.2976)

Thr Arg His Trp

C27H38N10O6 (598.2976)

Thr Arg Trp His

C27H38N10O6 (598.2976)

Thr Trp His Arg

C27H38N10O6 (598.2976)

Thr Trp Arg His

C27H38N10O6 (598.2976)

Trp His Arg Thr

C27H38N10O6 (598.2976)

Trp His Thr Arg

C27H38N10O6 (598.2976)

Trp Arg His Thr

C27H38N10O6 (598.2976)

Trp Arg Thr His

C27H38N10O6 (598.2976)

Trp Thr His Arg

C27H38N10O6 (598.2976)

Trp Thr Arg His

C27H38N10O6 (598.2976)

LRPTL

C27H50N8O7 (598.3802)

APRKK

C26H50N10O6 (598.3915)

PI(18:1/0:0)

C27H51O12P (598.3118)

LPI 18:1

C27H51O12P (598.3118)

PG-PG

C27H51O12P (598.3118)

Linkckoside J

C32H54O10 (598.3717)

H-Phe-Met-D-Arg-Phe-NH2

C29H42N8O4S (598.305)

H-Phe-Met-Arg-Phe-NH2 acetate salt

C29H42N8O4S (598.305)

1,3,3-trimethyl-2-[2-[2-phenyl-3-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclopent-2-en-1-ylidene]ethylidene]indole,tetrafluoroborate

C37H39BF4N2 (598.3142)

Tocofenoxate

C37H55ClO4 (598.3789)

Desethyl Dabigatran Etexilate Carboxamide

C32H38N8O4 (598.3016)

C30H54O6SSi2

C30H54O6SSi2 (598.3179)

2,3-Dihydrosalannin

C34H46O9 (598.3142)

A limonoid that is the 2,3-dihydro derivative of salannin. It has been isolated from Azadirachta indica.

Forskoditerpenoside D

C30H46O12 (598.2989)

A diterpene glycoside that is labd-14-en-11-one substituted by beta-acetoxy groups at positions 6 and 7, an epoxy group between positions 8 and 13 and a beta-D-glucopyranosyloxy group at position 1 (the 1alpha stereoisomer). Isolated from the whole plant of Coleus forskohlii, it shows relaxative effects on isolated guinea pig tracheal spirals in vitro.

Berbamuninium(2+)

C36H42N2O6+2 (598.3043)

5-O-mycaminosyltylonolide(1+)

C31H52NO10+ (598.3591)

An organic cation that is the conjugate acid of 5-O-mycaminosyltylonolide, obtained by protonation of the tertiary amino group; major species at pH 7.3.

(1R)-1,2,3,4-tetrahydro-1-[[4-[2-hydroxy-5-[[(1R)-1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]phenyl]methyl]-6-methoxy-2-methyl-7-isoquinolinol

C36H42N2O6+2 (598.3043)

1-Oleoylglycerophosphoinositol

C27H51O12P (598.3118)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C31H51O9P (598.3271)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C31H51O9P (598.3271)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C31H51O9P (598.3271)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0)

C31H51O9P (598.3271)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (E)-octadec-9-enoate

C27H51O12P (598.3118)

2-[3,4-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;hexadecanoic acid

C28H54O13 (598.3564)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

(1R,3R,4S,5S,6S,6S,8R,10E,13R,14E,16E,20R,21R,24S)-6-[(E)-But-2-en-2-yl]-3,24-dihydroxy-21-methoxy-5,11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2-oxane]-2-one

C35H50O8 (598.3506)

CID 154573495

C32H57NO7P+ (598.3872)

(2R,3R,4S,5S,6R)-2-[[7-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]oxy]-2-ethenyl-2,4b,8,8-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-3H-phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

4-(dimethylamino)-N-[[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-methoxyphenyl)urea

C33H50N4O6 (598.373)

4-(dimethylamino)-N-[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

1-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-methoxyphenyl)urea

C33H50N4O6 (598.373)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

1-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

4-(dimethylamino)-N-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

1-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

4-(dimethylamino)-N-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

4-(dimethylamino)-N-[[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

1-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

4-(dimethylamino)-N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-methoxyphenyl)urea

C33H50N4O6 (598.373)

1-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

12b-O-[deca-2Z,4E-dienoyl]-13a-isobutyl-5-ene-7-oxo-4b-phorbol

C34H46O9 (598.3142)

[(2R)-1-hydroxy-3-[hydroxy-[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate

C27H51O12P (598.3118)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-octadec-9-enoate

C27H51O12P (598.3118)

2,3-dihydroxypropyl [3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-2-hydroxypropyl] hydrogen phosphate

C32H55O8P (598.3634)

Dgdg O-8:0_4:0

C27H50O14 (598.32)

Dgdg O-9:0_3:0

C27H50O14 (598.32)

Smgdg O-16:1_2:0

C27H50O12S (598.3023)

Smgdg O-15:1_3:0

C27H50O12S (598.3023)

Smgdg O-13:1_5:0

C27H50O12S (598.3023)

Smgdg O-14:1_4:0

C27H50O12S (598.3023)

Dgdg O-10:0_2:0

C27H50O14 (598.32)

PMeOH 28:4

C32H55O8P (598.3634)

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C32H54O10 (598.3717)

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C32H54O10 (598.3717)

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C32H54O10 (598.3717)

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C32H55O8P (598.3634)

(1-pentanoyloxy-3-phosphonooxypropan-2-yl) (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C32H55O8P (598.3634)

(1-phosphonooxy-3-propanoyloxypropan-2-yl) (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C32H55O8P (598.3634)

(1-heptanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C32H55O8P (598.3634)

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C32H55O8P (598.3634)

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C32H55O8P (598.3634)

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C32H55O8P (598.3634)

12b-O-[deca-2E,4Z-dienoyl]-13a-(2-methylbutyl)-4b-phorbol

C35H50O8 (598.3506)

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C32H55O8P (598.3634)

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C32H55O8P (598.3634)

[1-phosphonooxy-3-[(E)-tridec-8-enoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C32H55O8P (598.3634)

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C32H55O8P (598.3634)

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C32H55O8P (598.3634)

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C32H55O8P (598.3634)

2-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C31H53NO8P+ (598.3509)

2-[[2-acetyloxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H57NO7P+ (598.3872)

2-[[2-hexanoyloxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H57NO7P+ (598.3872)

2-[[2-butanoyloxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C32H57NO7P+ (598.3872)

2-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C31H53NO8P+ (598.3509)

2-[hydroxy-[2-hydroxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C32H57NO7P+ (598.3872)

Berbamuninium(2+)

C36H42N2O6 (598.3043)

Dication of berbamunine arsing from protonation of both tertiary amino groups; major species at pH 7.3.

BisMePA(27:4)

C32H55O8P (598.3634)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MGDG O-23:4;O

C32H54O10 (598.3717)

DGMG 12:0

C27H50O14 (598.32)

SQMG 19:0

C28H54O11S (598.3387)

DGGA 21:4;O

C30H46O12 (598.2989)

DGGA 22:3

C31H50O11 (598.3353)

MGGA 23:3

C32H54O10 (598.3717)

PA O-29:5;O

C32H55O8P (598.3634)

PA P-16:1/13:3;O

C32H55O8P (598.3634)

PA P-18:1/11:3;O

C32H55O8P (598.3634)

PA 20:2/8:3;O

C31H51O9P (598.3271)

PA 20:4/8:1;O

C31H51O9P (598.3271)

PA 28:5;O

C31H51O9P (598.3271)

PA 11:0_18:4

C32H55O8P (598.3634)

PA 29:4

C32H55O8P (598.3634)

PG O-18:0/4:1;O2

C28H55O11P (598.3482)

PG O-22:1;O2

C28H55O11P (598.3482)

PG 16:0/5:1;O2

C27H51O12P (598.3118)

LPI 0:0/18:1

C27H51O12P (598.3118)

LPI 18:1/0:0

C27H51O12P (598.3118)

PI O-14:0/4:1

C27H51O12P (598.3118)

PI O-14:1/4:0

C27H51O12P (598.3118)

PI O-16:1/2:0

C27H51O12P (598.3118)

PI O-18:1

C27H51O12P (598.3118)

PI P-14:0/4:0

C27H51O12P (598.3118)

PI P-14:0/4:0 or PI O-14:1/4:0

C27H51O12P (598.3118)

PI P-16:0/2:0

C27H51O12P (598.3118)

PI P-16:0/2:0 or PI O-16:1/2:0

C27H51O12P (598.3118)

PI P-18:0

C27H51O12P (598.3118)

PI P-18:0 or PI O-18:1

C27H51O12P (598.3118)

PEth 26:5;O

C31H51O9P (598.3271)

PEth 27:4

C32H55O8P (598.3634)

PM 27:5;O

C31H51O9P (598.3271)

PM 28:4

C32H55O8P (598.3634)

ST 24:2;O6;GlcA

C30H46O12 (598.2989)

ST 25:1;O5;GlcA

C31H50O11 (598.3353)

ST 26:0;O4;GlcA

C32H54O10 (598.3717)

ST 28:6;O3;GlcA

C34H46O9 (598.3142)

ST 29:5;O2;GlcA

C35H50O8 (598.3506)

ST 24:3;O7;Hex

C30H46O12 (598.2989)

ST 25:2;O6;Hex

C31H50O11 (598.3353)

ST 26:1;O5;Hex

C32H54O10 (598.3717)

ST 28:7;O4;Hex

C34H46O9 (598.3142)

ST 29:6;O3;Hex

C35H50O8 (598.3506)

LPI(18:1)

C27H51O12P (598.3118)

-

1-(7-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]-1h,2h,3h,3ah,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,6-tetrol

C32H54O10 (598.3717)

(1r,2r,8s,17r,19s)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

2-({9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

ethyl 6-[11-(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-3,7,10-trioxo-1h,2h,4h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxohept-5-enoate

C34H46O9 (598.3142)

(1r,2r,6s,7s,8r,10s,11s,12r,16r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-5-one

C35H50O8 (598.3506)

(3s,6r,15as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-[(4-methoxyphenyl)methyl]-3-[6-(oxiran-2-yl)-6-oxohexyl]-3h,6h,9h,12h,13h,14h,15h,15ah-pyrido[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C32H46N4O7 (598.3366)

(2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

5-hydroxy-2,6,13,17,17-pentamethyl-6-(4-methylpenta-1,3-dien-1-yl)-16-[(3,4,5-trihydroxyoxan-2-yl)oxy]-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-1(20),11-dien-8-one

C35H50O8 (598.3506)

6-[2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H46O9 (598.3142)

3-benzyl-4,7-dihydroxy-2,6,10-trimethyl-9-pentyl-13-(sec-butyl)-3h,6h,9h,10h,13h,16h,17h,18h,18ah-pyrrolo[1,2-d]1-oxa-4,7,10,13-tetraazacyclohexadecane-1,11,14-trione

C33H50N4O6 (598.373)

10-(acetyloxy)-16-[5-(3,3-dimethyloxiran-2-yl)-2-oxo-5h-furan-3-yl]-2,6,6,11-tetramethyl-8-oxo-7-oxapentacyclo[13.3.1.0¹,¹⁵.0²,¹².0⁵,¹¹]nonadecan-3-yl acetate

C34H46O9 (598.3142)

(1r,2r,3r,3as,3bs,5r,7s,9ar,9br,11ar)-1-[(2r,6s)-7-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C32H54O10 (598.3717)

(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-{[(2r)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-methylbutanimidic acid

C30H42N6O7 (598.3115)

(2s)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

5,7,9-tris(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate

C34H46O9 (598.3142)

6-(but-2-en-2-yl)-3,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

(3s,6r,9s,15as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-[(4-methoxyphenyl)methyl]-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}-3h,6h,9h,12h,13h,14h,15h,15ah-pyrido[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C32H46N4O7 (598.3366)

n-[(2r)-1-{[(5r,6z,8e,10e,13s,14s,15r,16z)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl]pentanimidic acid

C34H50N2O7 (598.3618)

1,5,12,16,24,27-hexahydroxy-1,6,12,17,23,28-hexaazacyclotetratriaconta-5,16,23,27-tetraene-2,13-dione

C28H50N6O8 (598.369)

methyl (1r,2s,5s)-10,14-dihydroxy-2-(prop-1-en-2-yl)-16-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C38H46O6 (598.3294)

methyl 10,14-dihydroxy-2-(prop-1-en-2-yl)-16-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C38H46O6 (598.3294)

1-(7-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]-1h,2h,3h,3ah,4h,5h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,5-tetrol

C32H54O10 (598.3717)

6-(but-2-en-2-yl)-3,21',24'-trihydroxy-5,11',13',18',22'-pentamethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

5,8-bis(acetyloxy)-2,6,10,10-tetramethyl-7-[(3-phenylprop-2-enoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl hexanoate

C34H46O9 (598.3142)

(3e,6r)-6-[(1r,2r,3as,3bs,9ar,9br,11ar)-2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H46O9 (598.3142)

6-(acetyloxy)-3-ethenyl-3,4a,7,7,10a-pentamethyl-1-oxo-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-octahydronaphtho[2,1-b]pyran-5-yl acetate

C30H46O12 (598.2989)

(1r,2r,4s,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

(3r,6s,9r,10r,13s,18as)-3-benzyl-13-[(2s)-butan-2-yl]-4,7-dihydroxy-2,6,10-trimethyl-9-pentyl-3h,6h,9h,10h,13h,16h,17h,18h,18ah-pyrrolo[1,2-d]1-oxa-4,7,10,13-tetraazacyclohexadecane-1,11,14-trione

C33H50N4O6 (598.373)

(1r,2r,3s,8r,10r,11r,15r,16s)-3-(acetyloxy)-15-[(5s)-5-[(2r)-3,3-dimethyloxiran-2-yl]-2-oxo-5h-furan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

C34H46O9 (598.3142)

ethyl 6-[(1r,3ar,4s,5ar,9as,11s,11ar)-11-(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-3,7,10-trioxo-1h,2h,4h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxohept-5-enoate

C34H46O9 (598.3142)

(1'r,2r,4s,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-4,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-2-{[(3ar,5as,7s,9as,11as)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

(1s,3s,4s,9s,10s,13s,15s,17s,18s,19s,24s,25s)-25-(acetyloxy)-4,8,8,19,23,23-hexamethyl-2,14,16,28,29-pentaoxaoctacyclo[15.10.1.1¹³,¹⁸.0³,¹².0³,¹⁵.0⁴,⁹.0¹⁸,²⁷.0¹⁹,²⁴]nonacosa-11,26-dien-10-yl acetate

C34H46O9 (598.3142)

2-methyl-n-[(2r)-1-oxo-1-{[(5r,6e,8e,10e,13s,14s,15r,16e)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}propan-2-yl]propanimidic acid

C33H46N2O8 (598.3254)

(2r,3r,4s,5s,6r)-2-{[(3ar,5as,7s,9as,11as)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

3-(acetyloxy)-15-[5-(3,3-dimethyloxiran-2-yl)-2-oxo-5h-furan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

C34H46O9 (598.3142)

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

2-{[2-({2-[(2-{[(1-{2-[(2-amino-1,3-dihydroxypropylidene)amino]acetyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanimidic acid

C26H46N8O8 (598.3438)

(1s,2s,5r,7r,9r,11s)-9-benzoyl-11-[(6e)-3,8-dimethylnona-2,6-dien-1-yl]-4,4,8,8-tetramethyl-2-(2-methylprop-1-en-1-yl)-3-oxatetracyclo[7.3.1.1⁷,¹¹.0¹,⁵]tetradecane-10,12,13-trione

C39H50O5 (598.3658)

(1r,2r,4r,6r,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

(1s,2s,5r,7r,9r,11s)-9-benzoyl-11-[(2e,6e)-3,8-dimethylnona-2,6-dien-1-yl]-4,4,8,8-tetramethyl-2-(2-methylprop-1-en-1-yl)-3-oxatetracyclo[7.3.1.1⁷,¹¹.0¹,⁵]tetradecane-10,12,13-trione

C39H50O5 (598.3658)

(2s)-2-{[(2s)-2-[(2-{[(2s)-2-({[(2r)-1-(2-{[(2s)-2-amino-1,3-dihydroxypropylidene]amino}acetyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanimidic acid

C26H46N8O8 (598.3438)

3-[(2r,5s,8s,11r,14s)-3,6,9,12,15-pentahydroxy-14-(1h-indol-3-ylmethyl)-8-isopropyl-5-methyl-11-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propanoic acid

C30H42N6O7 (598.3115)

n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-(2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-[(2s)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

2',3'-dihydrosalannin

C34H46O9 (598.3142)

12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

2-{[2-({9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

(2s,5r,6s,9r,13s,16s,18r)-5-hydroxy-2,6,13,17,17-pentamethyl-6-[(1e)-4-methylpenta-1,3-dien-1-yl]-16-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-1(20),11-dien-8-one

C35H50O8 (598.3506)

(1s,4ar,5r,7s,7as)-7-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-5-yl (2e,4e)-5-[(1r,2r)-1,2-dihydroxy-2,6,6-trimethylcyclohexyl]-3-methylpenta-2,4-dienoate

C30H46O12 (598.2989)

(1'r,2s,3r,4's,5s,6s,8'r,10'z,13'r,14'z,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,21',24'-trihydroxy-5,11',13',18',22'-pentamethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

3-[3,6,9,12,15-pentahydroxy-14-(1h-indol-3-ylmethyl)-8-isopropyl-5-methyl-11-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propanoic acid

C30H42N6O7 (598.3115)

ethyl (6r)-6-[(1r,3ar,5ar,9as,11s,11ar)-11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C34H46O9 (598.3142)

2-{[3,6-dioxo-5-(pentyloxy)cyclohexa-1,4-dien-1-yl]methyl}-6-{[(4s)-4-hydroxyoctadecyl]oxy}cyclohexa-2,5-diene-1,4-dione

C36H54O7 (598.3869)

14-(acetyloxy)-6-(furan-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 3-methylbutanoate

C34H46O9 (598.3142)

(2r,3s,4s,5r,6r)-2-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[(1s,4s,5s,6s,9s,10r,13r)-6-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}oxane-3,4,5-triol

C31H50O11 (598.3353)

(1s,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

(1r,3br,4s,5r,5as,7r,9s,9ar,9br,11as)-4,7,9-tris(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate

C34H46O9 (598.3142)

(3r,6s,9r,10s,13s,18as)-3-benzyl-13-[(2s)-butan-2-yl]-4,7-dihydroxy-2,6,10-trimethyl-9-pentyl-3h,6h,9h,10h,13h,16h,17h,18h,18ah-pyrrolo[1,2-d]1-oxa-4,7,10,13-tetraazacyclohexadecane-1,11,14-trione

C33H50N4O6 (598.373)

2,7,8-trihydroxy-3-tridecyl-6-undecyloxanthrene-1,4-dione

C36H54O7 (598.3869)

(2s,8r,17s)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate

C30H46O12 (598.2989)

(2s)-n-[(2r)-5-carbamimidamido-1-hydroxypentan-2-yl]-1-[(2r)-2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

(1r,2s,4s,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(furan-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 3-methylbutanoate

C34H46O9 (598.3142)

(1s,2r,4s,5r,6s,7s,8r,9s)-5,8-bis(acetyloxy)-2,6,10,10-tetramethyl-7-{[(2e)-3-phenylprop-2-enoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl hexanoate

C34H46O9 (598.3142)

2-{[3,6-dioxo-5-(pentyloxy)cyclohexa-1,4-dien-1-yl]methyl}-6-[(4-hydroxyoctadecyl)oxy]cyclohexa-2,5-diene-1,4-dione

C36H54O7 (598.3869)

ethyl 6-[11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C34H46O9 (598.3142)

2-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-({6-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl}methoxy)oxane-3,4,5-triol

C31H50O11 (598.3353)

(1r,2r,3r,3as,3bs,6r,7s,9ar,9br,11ar)-1-[(2r,6s)-7-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-7-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-1h,2h,3h,3ah,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthrene-2,3,3b,6-tetrol

C32H54O10 (598.3717)

(1s,2r,3r,5r,10s,11r,12r,15r,16r)-10-(acetyloxy)-16-[(5s)-5-[(2r)-3,3-dimethyloxiran-2-yl]-2-oxo-5h-furan-3-yl]-2,6,6,11-tetramethyl-8-oxo-7-oxapentacyclo[13.3.1.0¹,¹⁵.0²,¹².0⁵,¹¹]nonadecan-3-yl acetate

C34H46O9 (598.3142)

(1s,2s,6s,7s,9r,11s,13s,14r,15s,16s,17s)-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-11-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate

C30H46O12 (598.2989)

(2s)-n-[(2s)-5-carbamimidamido-1-hydroxypentan-2-yl]-1-[(2r)-2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl 2-methylbut-2-enoate

C34H46O9 (598.3142)